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Hospital Clínic-IDIBAPS, University of Barcelona and CIBERehd, Barcelona, SpainSummary progressive liver tissue ﬁbrogenesis and extensive vascularThe development of portal hypertension is a common conse-
quence of chronic liver diseases leading to the formation of esoph-
ageal and gastric varices responsible for variceal bleeding,
associated with a high mortality rate, as well as other severe com-
plications such as portosystemic encephalopathy and sepsis. Mea-
surement of hepatic venous pressure gradient (HVPG) and upper
GI endoscopy are considered the gold standards for portal hyper-
tension assessment in patients with cirrhosis. However, both
types of investigation are invasive and HVPGmeasurement is rou-
tinely available and/or performed with adequate standards only
in expert centres. There is thus a need for non invasive methods
able to predict, with acceptable diagnostic accuracy, the progres-
sion of portal hypertension toward the levels of clinically signiﬁ-
cant (i.e. HVPG P10 mmHg) and severe (HVPG P12 mmHg) as
well as the presence and the size of oesophageal varices. Transient
elastography (TE) is a novel non invasive technology that allows
measuring liver stiffness and that has gained popularity over the
past few years. Although TE has been initially proposed to assess
liver ﬁbrosis, a good correlation has been reported between liver
stiffness values and HVPG as well as the presence of oesophageal
varices, suggesting that it could be an interesting tool for the non
invasive evaluation of portal hypertension. This review is aimed at
discussing the advantages and limits of TE and the perspectives
for its rationale use in clinical practice for the management of
patients with portal hypertension.
 2011 European Association for the Study of the Liver. Published
by Elsevier B.V. All rights reserved.Introduction
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E-mail address: laurent.castera@bjn.aphp.fr (L. Castera).changes occurring bothwithin the liver and in the splanchnic com-
partment [1]. Established evidence indicates that CLD are charac-
terized by a progressive intrahepatic vascular remodelling with
capillarization of sinusoids, ﬁbrogenesis, neo-angiogenesis, and
development of intrahepatic shunts, which would lead to
increased hepatic resistance leading to increased portal pressure
and decreased effective hepatocyte perfusion leading to liver fail-
ure. It is alsowell established that increased hepatic vascular resis-
tance in cirrhosis is not only a mechanical consequence of the
hepatic architectural disorder (so-called ‘‘static component’’).
Indeed, the extensive accumulation of ﬁbrillar extracellularmatrix
is associated with the active contraction of myoﬁbroblasts, acti-
vated hepatic stellate cells, and vascular smooth-muscle cells
of the intrahepatic veins in a tissue microenvironment charac-
terized by a net predominance of vasoconstrictors (so-called
‘‘dynamic component’’) [2]. An additional determinant of portal
hypertension is the progressive increase in blood ﬂow in the
portal veins, which is established through splanchnic arteriolar
vasodilatation caused by an excessive release of endogenous
vasodilators. The increase in portal blood ﬂow aggravates the
increase in portal pressure and contributes to the formation of
an extensive network of portosystemic collaterals that may
divert as much as 80% of portal blood ﬂow. These are responsi-
ble for the formation of esophageal and gastric varices, involved
in variceal bleeding, associated with a high mortality rate [3]. In
addition, collateral vessels result in shunting of portal blood into
the systemic circulation, causing high systemic concentrations
of several substances normally metabolized by the liver. These
in turn contribute to severe complications of cirrhosis, such as
portosystemic encephalopathy.
An increase in portal pressure (i.e. >6 mmHg) can be already
detected by the measurement of the hepatic vein pressure gradi-
ent (HVPG) in patients with histologically deﬁned advanced
ﬁbrosis. However, complications of portal hypertension, i.e.
development of esophageal varices, may start when HVPG
increases over 10 mmHg, which deﬁnes what is known as ‘‘clini-
cally signiﬁcant portal hypertension’’ (Baveno IV) and clinical
decompensation in form of bleeding, ascites, hepatic encephalop-
athy, and renal impairment, may develop when HVPG increases
over a threshold value of 10–12 mmHg [4].
Beyond these classic clinical concepts, the detection of
increased portal pressure in the context of chronic ﬁbrogenic12 vol. 56 j 696–703
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diseases of the liver has profound implications and currently rep-
resents a key reference standard for the development of a patho-
physiological classiﬁcation of cirrhosis [5]. At present the stage of
‘‘cirrhosis’’ is either deﬁned by the histopathological evidence of
METAVIR stage F4 or ISHAK S5–S6 or more in general by the pres-
ence of the so-called ‘‘regenerative’’ or ‘‘cirrhotic nodules’’. In rou-
tine clinical practice, such deﬁnition does not allow making the
distinction between a ﬁbrogenic process that is still in progress
but potentially reversible from a more advanced stage of the liver
disease that becomes irreversible. Indeed, cirrhosis encompasses
a pathological spectrum which is neither static nor uncompro-
misingly progressive but rather dynamic and bidirectional, espe-
cially when treatment against the causative agent of tissue
damage can be introduced with success at this stage of the dis-
ease. Thus, there is a pressing need to redeﬁne cirrhosis in a man-
ner that better recognizes its underlying relationship to portal
hypertension and tissue ﬁbrosis, and more faithfully reﬂects its
progression, reversibility, and prognosis. The need becomes par-
ticularly appropriate given the increasing use of effective antivi-
ral treatments in patients with HBV and HCV cirrhosis and the
possibility of introducing effective antiﬁbrotic agents. In this con-
text, it is essential to deﬁne favorable or unfavorable endpoints
that correlate with a distinct clinical outcome in patients with
cirrhosis.
All these considerations apply particularly to the stage of cir-
rhosis deﬁned as ‘‘compensated’’, characterized by the paucity or
absence of clinical signs. Currently, compensated cirrhosis is sub-
classiﬁed in two stages: without varices (stage 1) or with varices
(stage 2). In addition, this distinction could be further reﬁned as
(a) no portal hypertension; (b) portal hypertension that is not
clinically-signiﬁcant (HVPG <10 mmHg); and (c) clinically signif-
icant portal hypertension (HVPG P10 mmHg) [6]. Regardless, in
most cases presenting in clinical practice, it is practically impos-
sible to allocate a patient with compensated cirrhosis in one of
these substages without performing HVPG measurement and
upper GI endoscopy. Both types of investigation are invasive
and HVPG measurement is routinely available and/or performed
with adequate standards only in expert centres. Along these lines,
the need of non invasive methods able to predict with acceptable
diagnostic accuracy the progression of portal hypertension
toward the levels of clinically signiﬁcant (i.e. P10 mmHg) and
severe (i.e.P12 mmHg) becomes absolutely relevant. In this con-
text, it would be also useful to have non invasive methodologies
able to predict the presence or absence of esophageal and gastric
varices. However, it should be stressed that the available non
invasive methods are not expected to replace either HVPG mea-
surement or upper GI endoscopy, but rather to offer a mean for
the rapid discrimination of different steps of progression within
the stage of compensated cirrhosis. This will greatly help allocat-
ing cirrhotic patients in different categories of risk and guide the
need of further evaluation with HVPGmeasurement and upper GI
endoscopy.How to evaluate portal hypertension
Is HVPG measurement a relevant gold standard for portal
hypertension assessment?
HVPG is an accurate, reproducible and safe way of measuring
portal pressure in patients with cirrhosis of any aetiology (withJournal of Hepatology 201the exception of primary biliary cirrhosis) [7]. HVPG is considered
to be the best surrogate indicator of prognosis in patients with
cirrhosis [8]. This is due to the fact that HVPG elevation has been
found in multiple studies to carry independent prognostic value
for most relevant events in the course of cirrhosis (Table 1).
Brieﬂy, HVPG has been found to correlate with the risk of forma-
tion of varices, of clinical decompensation and of development of
hepatocellular carcinoma (HCC) in patients with ‘‘Stage 1’’ com-
pensated cirrhosis [4,9,10]. Measurement of HVPG can distin-
guish sub-stages within compensated cirrhosis, according to
whether HVPG is <10 or P10 mmHg, the latter having an
increased risk of decompensation, HCC and death. Based on this,
it has been proposed that preventive therapies may be started
when HVPG isP10 mmHg, since lowering portal pressure below
10 mmHg is likely to result in prevention of clinical decompensa-
tion, and death [3]. Relevance of HVPG measurements is further
emphasized by the ﬁndings that HVPG above 16 mmHg corre-
lates with increased risk of death [7,11,12], that during acute var-
iceal bleeding, HVPG >20 mmHg is the best independent
prognostic marker [13–16] and that measurement of changes in
HVPG during the treatment of portal hypertension allow to deﬁne
a group of patients with an optimal outcome (the hemodynamic
‘‘responders’’) [17–21] (Table 1). Recent studies further suggest
that patients showing a drop in HVPG P10% of baseline 15 min
after the IV administration of propranolol (0.15 mg/kg) (‘‘acute
hemodynamic responders’’) [22,23] also have a lower risk of
bleeding and death. Finally, a pre-operative HVPG P10 mmHg
denotes a poor prognostic of liver resection in patients with small
HCC; HVPG P6 mmHg 1-year after liver transplantation, is the
best indicator of a poor outcome [24] and successful treatment
of viral cirrhosis [25–27], and alcohol withdrawal [28] are associ-
ated with a signiﬁcant decrease in HVPG. Because of this, it has
been proposed that serial measurements of HVPG could be used
for assessing progression/regression of ﬁbrosis/cirrhosis in
chronic liver diseases of any aetiology [7]. Details on the tech-
nique and precautions for accurate measurements are described
in depth in recent reviews [7,11].
Is upper GI endoscopy a relevant gold standard for portal
hypertension assessment?
Another ‘‘gold standard’’ in the evaluation of portal hypertension
is the use of upper GI endoscopy for the detection of varices [6].
By far, endoscopy is the best way of assessing the presence of
oesophageal varices (OV), where its accuracy is much greater
than that of radiology (including multidetector CT-angiography)
[29–31]. Endoscopy has to be complemented sometimes with
endoscopic ultrasonography, especially in cases with suspected
isolated gastric varices. Endoscopy has the further advantage
of allowing to detect indicators of increased bleeding risk (the
red colour signs and ‘‘wale’’ marks) that cannot be detected
accurately by other imaging techniques [32]. Because of this, it
is recommended that any patient with cirrhosis should undergo
screening endoscopy at diagnosis, and repeat follow-up examin-
ations if no varices are found or if no preventive treatment is ini-
tiated in patients with ‘‘low-risk’’ varices (small varices without
red colour signs in a Child A patient) [6].
Both HVPG measurements and upper GI endoscopy are safe
but minimally invasive diagnostic techniques that carry patient
discomfort, increase the burden for medical providers and
increased cost of medical care. Because of this, there is a clinical2 vol. 56 j 696–703 697
Table 1. Correlation between HVPG and complications of portal hypertension in patients with cirrhosis.
Clinical scenario HVPG value
Compensated cirrhosis
Risk of formation of varices ≥10 mmHg
Risk of clinical decompensation ≥10 mmHg
Risk of hepatocellular carcinoma ≥10 mmHg
Risk of variceal bleeding ≥12 mmHg
Risk of death ≥16 mmHg
Acute variceal bleeding
Risk of treatment failure and increased mortality ≥20 mmHg
Treatment of portal hypertension
   a) Pre-primary prophylaxis Formation of varices <10 mmHg or decrease in HVPG ≥10%*
   b) Primary prophylaxis First variceal haemorrhage ≤12 mmHg or decrease in HVPG ≥20%*
   c) Secondary prophylaxis Recurrent variceal bleeding, ascites, SBP, death ≤12 mmHg or decrease in HVPG ≥20%*
Resection of hepatocellular carcinoma Surgical risk (decompensation and death) ≥10 mmHg
⁄Chronic HVPG response (change in HVPG after 3–12 weeks on therapy); the criteria for a ‘‘good’’ HVPG response after acute IV propranolol is a decrease in HVPGP10% of
baseline values.
SBP, spontaneous bacterial peritonitis.
Reviewneed for non-invasive ways of assessing portal hypertensive
patients that could substitute for the need of hemodynamic mea-
surements and endoscopy. Let us state upfront that despite new
technological developments, all the efforts done up to now have
not resulted in such a substitute. However, as discussed in this
review, there have been substantial advances that may result in
a much better deﬁnition of patients in whom these procedures
are indicated, decreasing the number of patients that have to
be submitted to HVPG/endoscopy. Speciﬁcally, there is substan-
tial evidence indicating that transient elastography (TE) can be
quite effective in detecting patients with a high risk of having
(or not having) developed clinically signiﬁcant elevations of
HVPG or varices. Details on the principle and technique of TE
have been previously described [33,34].Diagnostic performance of transient elastography for portal
hypertension
Detection of clinically signiﬁcant portal hypertension
The performances of TE for detection of clinically signiﬁcant por-
tal hypertension are shown in Table 2. A good correlation
between liver stiffness values and HVPG has been initially
reported by Carrion et al. in 124 HCV patients with HCV recur-
rence after liver transplantation (Pearson coefﬁcient, 0.84; p
<0.001) [35]. The AUROCs for the diagnosis of portal hypertension
(HVPG P6 mmHg) and clinically signiﬁcant portal hypertension
were 0.93 and 0.94, respectively (Table 2). Several other groups
have conﬁrmed these results since in patients with chronic hep-
atitis C [36] or with other chronic liver diseases [37–39], with
AUROCs for detecting clinically signiﬁcant portal hypertension
ranging from 0.76 to 0.99 and TE cut-offs from 13.6 to 34.9 kPa
(Table 2). Interestingly, in the only study that analysed the results
according to the liver disease etiology [38], cut-offs were higher
in alcoholic cirrhosis than in viral cirrhosis (34.9 and 20.5 kPa,698 Journal of Hepatology 201respectively). Although these results are in keeping with ﬁndings
suggesting that cut-offs for cirrhosis diagnosis may be higher in
alcoholic liver disease [40,41], they need to be further conﬁrmed
in other series.
Another interesting ﬁnding is the fact that, although the cor-
relation was excellent for HVPG values below 10–12 mmHg, it
hardly reached statistical signiﬁcance for values above 12 mm
Hg [36]. This important observation suggests that beyond a cer-
tain degree of portal pressure (i.e. above 10–12 mmHg), the
development of portal hypertension becomes at least partially
independent from the simple accumulation of ﬁbrillar extracellu-
lar matrix responsible for the increase in liver stiffness. It is con-
sistent with the pathophysiology of portal hypertension where
several extra-hepatic factors such as the hyperdynamic circula-
tion, the splanchnic vasodilatation, and the resistance opposed
to portal blood ﬂow by the portosystemic collaterals contribute
to the rise in portal pressure [7,42]. Accordingly, TE is unlikely
to be useful in the monitoring the hemodynamic response to drug
therapy, the effect of which is mediated primarily by decreasing
the splanchnic blood ﬂow [4].
Conversely, repeated liver stiffness measurements over time
could be of interest during the ﬁrst year after liver transplanta-
tion to identify patients with severe hepatitis C recurrence at
an early stage [43]. Indeed, liver stiffness values together with
donor age and bilirubin levels were independent predictors in
multivariate analysis of portal hypertension (HVPG P6 mmHg)
and ﬁbrosis progression (ﬁbrosis stage >2) in HCV-infected liver
transplant recipients. These preliminary results are promising
but need to be validated by other groups [44] before implemen-
tation in clinical practice.
Detection of oesophageal varices
A correlation between liver stiffness values and the presence of
OV has also been reported [36,37,45–50]. AUROCs of TE for diag-
nosing the presence of OV ranged from 0.74 to 0.85 and cut-offs2 vol. 56 j 696–703
Table 2. Diagnostic performance of transient elastography for the detection of clinically signiﬁcant portal hypertension (HVPG P10 mm Hg).
Authors,
[Ref.]
Patients
(n)
Etiologies Study 
design
Prevalence of 
portal hyperten-
sion
(%)
Cut-offs
HVPG ≥10 mmHg
(kPa)
AUC Se
(%)
Sp
(%)
PPV
(%)
NPV
(%)
+LR -LR
Carrion 
et al., [35]
124 HCV-LT Pro. 
mono.
21 8.7* - 0.92 90 81 81 90 4.7 0.12
Vizzutti 
et al., [36]
61 HCV Pro.
mono.
77 13.6
17.6**
0.99
0.92
97
94
92
81
97
86
92
91
13.7
4.9
0.02
0.08
Sanchez-
Condé 
et al., [39]
38 HIV-HCV Pro.
mono.
74 14.0
23.0**
0.80
0.80
93
83
50
67
84
79
71
71
3.5
2.5
0.62
0.49
Lemoine 
et al., [38]
44
48
HCV
Alcohol
Retro.
mono.
77
83
20.5
34.9
0.76
0.94
63
90
70
88
88
97
35
64
2.1
7.5
0.53
0.13
Bureau 
et al., [37]
150 CLD Pro.
mono.
51 21.0 0.94 90 93 93 91 12.8 0.10
clinically significant
⁄Hepatic venous pressure gradient (HVPG) P6 mm Hg; ⁄⁄severe portal hypertension HVPG P12 mm Hg.
AUC, area under ROC curve; Se, sensitivity; Sp, speciﬁcity; +LR, positive likelihood ratio; LR, negative likelihood ratio; HCV, chronic hepatitis C; HCV-LT, liver transplant for
hepatitis C; CLD, chronic liver diseases; Pro. mono., prospective monocentric; Retro. mono., retrospective monocentric.
Table 3. Diagnostic performance of transient elastography for the detection of oesophageal varices (OV and LOV) in cirrhotic patients.
Authors,
[Ref.]
Patients
(n)
Etiologies Study
design
Child-Pugh
A (%)
End 
point
Prevalence
OV (%)
Cut-offs
(kPa)
AUC Se
(%)
Sp
(%)
PPV
(%)
NPV
(%)
+LR -LR Saved
endoscopy
(%)
Kazemi
et al., [45]
165 CLD Retro.
mono.
n.a. OV
LOV
45
28
13.9
19.0
0.83
0.84
95
91
43
60
57
48
91
95
1.7
2.3
0.13
0.14
66
69
Vizzutti
et al., [36]
47 HCV Pro.
mono.
60 OV 66 17.6 0.76 90 43 77 66 1.6 0.23 74
Pritchett
et al., [48]
211 CLD Retro.
mono.
n.a. OV
LOV
n.a.
37
19.5
19.8
0.74
0.76
76
91
66
56
56
91
82
55
2.2
2.1
0.36
0.16
n.a.
69
Bureau
et al., [37]
89 CLD Pro.
mono.
34 OV
LOV
72
48
21.1
29.3
0.85
0.76
84
81
71
61
2.9
2.1
0.22
0.31
81
71
Castera 
et al., [46]
70 HCV Retro.
mono.
100 OV
LOV
36
19
21.5
30.5
0.84
0.87
76
77
78
85
68
56
84
94
3.5
5.1
0.31
0.27
73
79
Pineda,
et al., [47]
102 HIV-HCV Pro.
multi.
76 CROV* 13 21.0 0.71 100 32 25 100 1.5 0.0 44
Nguyen 
et al. [49]
183
58
103
CLD
HCV/HBV
Alcohol
Retro.
mono.
63 LOV 22
17
25
48.0
19.8
47.2
0.76
0.73
0.77
73
89
85
73
55
64
44
27
44
90
97
93
2.7
2.0
2.4
0.37
0.20
0.23
73
60
69
Malik
et al., [50]
124 CLD Retro.
mono.
n.a. OV 51 20.0 0.85 n.a. n.a. 80 75 n.a. n.a. n.a.
⁄CROV: clinically relevant OV requiring primary prophylaxis of bleeding, i.e. patients carrying LOV or OV with red signs or Child-Pugh class C.
CLD, chronic liver diseases; HCV, chronic hepatitis C; HIV-HCV, co-infection with human deﬁciency virus and hepatitis C virus; HBV, hepatitis B virus; AUC, area under ROC
curve; Se, sensitivity; Sp, speciﬁcity; PPV & NPV, positive and negative predictive values; +LR & LR, positive and negative likelihood ratios; Pro. mono., prospective
monocentric; Pro. multi., prospective multicentric; Retro. mono., retrospective monocentric.
The percentage of saved endoscopy was calculated as the percentage of correctly classiﬁed patients by pooling true negative and true positive.
JOURNAL OF HEPATOLOGYfrom 13.9 to 21.5 kPa (Table 3). Sensitivity for the prediction of
the presence of OV was high (76–95%) but speciﬁcity was much
lower (43–78%).
A correlation between liver stiffness values and variceal size
was observed in some studies [37,45,46,48] whereas it was not
in others [36,47,49,50]. Cut-offs for the prediction of the presence
of large OV (LOV) were higher ranging from 19 to 48.0 kPa (Table
3). Sensitivity of TE for detecting LOV was also high (77–100%)
with much lower speciﬁcity (32–85%) (Table 3). In the only study
that analysed the results according to the etiology of the underly-
ing liver disease [49], cut-offs for detection of LOV were higher in
patients with alcoholic cirrhosis than in those with viral cirrhosisJournal of Hepatology 201(47.2 and 19.8 kPa, respectively), a ﬁnding consistent with what
has been reported for clinically signiﬁcant portal hypertension
[38]. Further studies are needed to conﬁrm these ﬁndings.
Overall, these results deserve several comments. First, most of
these studies have been conducted retrospectively in single cen-
ters on heterogeneous populations (mixing viral hepatitis- and
alcohol-related liver diseases) with small sample size (<100 in
most cases). Second, the prevalence of disease severity (propor-
tion of Child-Pugh A patients ranging from 34% to 100%) and var-
ices (proportion of patients with OV or LOV ranging from 36% to
72% and 19% to 48%, respectively) was highly variable from one
study to another. Third, the judgement criteria markedly differed2 vol. 56 j 696–703 699
Table 4. Diagnostic performance of other non invasive tools for the detection of oesophageal varices (OV and LOV) in cirrhotic patients.
Test,
[Ref.]
Patients
(n)
Etiologies Study
design
Child-Pugh
A (%)
End 
point
Prevalence
OV (%)
Cut-offs
(kPa)
AUC Se
(%)
Sp
(%)
PPV
(%)
NPV
(%)
+LR -LR Saved
endoscopy
(%)
Platelet
count, [54]
510 CLD Retro.
multi.
79 CROV* 28 89 0.65 55 75 49 80 2.17 0.61 66
AST/ALT
ratio, [54]
510 CLD Retro.
multi.
79 CROV* 28 1.1 0.64 71 57 60 82 1.63 0.52 61
APRI, [54] 510 CLD Retro.
multi.
79 CROV* 28 1.5 0.57 57 57 35 76 1.30 0.76 57
Forns’
index, [54]
510 CLD Retro.
multi.
79 CROV* 28 8.8 0.66 71 62 58 82 1.88 0.47 66
Lok
index, [54]
510 CLD Retro.
multi.
79 CROV* 28 1.5 0.70 71 68 50 84 2.25 0.42 69
Fib-4, [54] 510 CLD Retro.
multi.
79 CROV* 28 4.3 0.63 71 56 40 82 1.60 0.53 60
Fibroindex,
[54]
510 CLD Retro
multi.
79 CROV* 28 2.5 0.65 51 76 50 75 2.06 0.65 70
Fibrotest®,
[55]
99 CLD Retro.
mono.
42 LOV 72 0.85 0.77 84 53 86 50 1.78 0.28
PC/SDR,
[56]
218 CLD Pro.
multi.
51 OV 54 909 0.86 92 67 77 87 2.77 0.13 80
Capsule
endoscopy,
[57]
288 CLD Pro.
multi.
69 OV
LOV
63
27
n.a.
n.a.
n.a.
n.a.
84
78
88
96
92
87
77
92
7.00
19.50
0.18
0.23
86
79
Lapalus
et al., [58]
120 CLD Pro.
multi.
48 OV
LOV
62
29
n.a.
n.a.
n.a.
n.a.
77
77
86
88
90
75
69
90
5.42
6.69
0.28
0.26 85
⁄CROV, clinically relevant OV requiring primary prophylaxis of bleeding, i.e. patients carrying LOV or OV with red signs or Child-Pugh class C.
CLD, chronic liver diseases; AUC, area under ROC curve; Se, sensitivity; Sp, speciﬁcity; PPV & NPV, positive and negative predictive values; +LR & LR, positive and negative
likelihood ratios; Pro. multi., prospective multicentric; Retro. mono., retrospective monocentric; Retro. multi., retrospective multicentric.
The percentage of saved endoscopy was calculated as the percentage of correctly classiﬁed patients by pooling true negative and true positive.
Reviewbetween studies: presence of OV only in two of them [36,50],
presence of LOV only in one of them [49] and presence of both
in four [37,45,46,48]. However, according to the latest Baveno V
recommendations [6], primary prophylaxis for variceal bleeding
is indicated in patients with clinically relevant OV (CROV) (i.e.
patients with LOV or with small OV and red wale marks or Child
C class), a criteria that has been taken into account in one study
only [47]. Also the assessment of OV size was rather subjective:
no details were provided in most of these studies regarding the
quality of this assessment even though endoscopy is known to
be an imperfect gold standard with considerable inter-observer
variability for detecting and grading varices [51]. Fourth, the pro-
posed cut-offs for detecting OV or LOV were discrepant between
studies, thus the optimal cut-off remains to be deﬁned. Finally,
the diagnostic accuracy (speciﬁcity and likelihood ratios) reported
so far is much too low for a reliable use in clinical practice.
Thus, from the data currently available, diagnostic perfor-
mances of TE are acceptable for the prediction of clinically signif-
icant portal hypertension but far from satisfactory to conﬁdently
predict the presence of OV in clinical practice and to screen cir-
rhotic patients without endoscopy.Comparison of transient elastography with other non invasive
tools
Detection of portal hypertension
Several biological parameters have been proposed for the non
invasive detection of clinically signiﬁcant portal hypertension700 Journal of Hepatology 201including prothrombin time [37], a score combining platelet
count and total bilirubin [52], and FibroTest [53]. In a popula-
tion of 61 Korean patients, Park et al. [52] have shown that a score
combining platelet count and total bilirubin had an AUROC of
0.91 for predicting clinically signiﬁcant portal hypertension with
a 88% sensitivity and 86% speciﬁcity at a cut-off of 1.0. In 92
French patients with cirrhosis, the FibroTest had an AUROC of
0.79 for predicting severe portal hypertension (HVPG P12 mm
Hg) [53]. In the only study comparing TE to other non invasive
tests, performance of TE and prothrombin time did not differ
(AUROC 0.95 vs. 0.89, respectively) [37]. Combining TE (at a
cut-off of 21 kPa) and prothrombin time (at a cut-off of 82.5%)
allowed classifying correctly 73% of patients.
Detection of oesophageal varices
Several non invasive tools have been proposed for the detection
of OV including routine biological parameters [54], FibroTest
[55], combination of simple biological and ultrasound parameters
[56], and more recently oesophageal capsule endoscopy [57,58].
The performances of these tools are summarized in Table 4. The
AUROCs of serum markers ranged from 0.57 to 0.86, with higher
sensitivity (51–92%) than speciﬁcity (53–76%). In the largest
study to date comparing retrospectively a panel of serum mark-
ers (platelet count, AST/ALT ratio, APRI, Forns index, Lok index,
FIB-4, and Fibroindex) in more than 500 patients with chronic
liver diseases, the combination of Lok index (cut-off = 1.5) and
Forns index (cut-off = 8.8) had the best diagnostic performance
(AUROC of 0.80 and negative predictive value of 90%) for predict-
ing clinically relevant OV [54].2 vol. 56 j 696–703
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Sensitivity of oesophageal capsule endoscopy for the detec-
tion of LOV ranged from 77% to 78% and speciﬁcity from 88% to
96% [57,58] (Table 4). These preliminary results suggest that
oesophageal capsule endoscopy is a promising tool for the detec-
tion of OV. However, further studies comparing this technology
to other available non invasive tools such as TE are awaited.
Three studies only compared TE with other non invasive tools
thus far [45,46,59]. TE did not perform better for the detection of
OV and LOV in patients with chronic hepatitis C than serum
markers [46]. For instance, at a cut-off of 30.5 kPa, TE predicted
the presence of LOV with 79% accuracy as compared with 79%
for prothrombin time, 77% for Lok index, 76% for AST/ALT ratio
and platelet count, 64% for FibroTest, and 63% for APRI, respec-
tively. Similarly, in another study [45], TE performances did not
differ from those of platelet count/spleen diameter ratio for
detection of LOV. In a cohort of 401 Korean patients with chronic
hepatitis B (training set 280; validation set 121), TE had similar
diagnostic performances than spleen diameter and platelet count
for detection of clinically relevant OV [59]. However, the combi-
nation of liver stiffness with spleen diameter and platelet count
(referred as LSPS for LSM-Spleen diameter to Platelet ratio Score)
increased diagnostic accuracy. Indeed, LSPS had a signiﬁcantly
better AUROC than TE alone (0.95 vs. 0.88, respectively; p
<0.001). At a cut-off <3.5, LSPS had a 94.0% negative predictive
value and a 94.2% positive predictive value at a cut-off >5.5. Over-
all, upper GI endoscopy could be saved in 90.3% patients. These
promising results suggest that like for the diagnosis of liver ﬁbro-
sis [60], combining two unrelated methods such as TE and serum
markers or ultrasonography may increase accuracy for detecting
OV but need to be further validated.
Prediction of clinical outcome
Since the initial report [61], suggesting that liver stiffness may be
of prognostic value in patients with cirrhosis, other groups have
conﬁrmed these ﬁndings [62–64]. Very recently, a French study
conducted in 100 patients with chronic liver diseases and a 2-
year follow-up, reported that liver stiffness values may be as
effective as HVPG in predicting clinical decompensation and por-
tal hypertension-related complications [65]. For instance, at a
cut-off of 21.1 kPa, TE had a 100% negative predictive value for
the occurrence of portal hypertension related complications, sug-
gesting that if such results are further conﬁrmed, TE could be
used as a screening test for clinical outcome [66].Limitations of transient elastography
Liver stiffness measurements can be difﬁcult in obese patients or
with narrow intercostal space and impossible in patients with
ascites [33]. Although TE reproducibility has been shown to be
excellent for inter-observer and intra-observer agreement
[67,68], its applicability may not be as good as initially thought.
Indeed, in our experience over 5 years in more than 13,000 exam-
inations, liver stiffness measurements were not interpretable in
nearly one in ﬁve cases (failure to obtain any measurement in
4% and unreliable results not meeting manufacturer’s recommen-
dations in 17%) [69]. The principal reasons were obesity,
particularly increased waist circumference, and limited operator
experience. These results emphasize the need for adequate oper-
ator training and for technological improvements in speciﬁcJournal of Hepatology 201patient populations such as those with non alcoholic fatty liver
disease.
Finally, as the liver is an organ wrapped in a distensible but
non-elastic envelope (Glisson’s capsula), additional space-occu-
pying tissue abnormalities, such as oedema and inﬂammation,
cholestasis and congestion, may interfere with liver stiffness
measurement (LSM), independently of ﬁbrosis. Indeed, as previ-
ously mentioned, the extent of necro-inﬂammatory activity has
been shown to inﬂuence TE measurements in patients with viral
hepatitis with a steady increase of liver stiffness values in parallel
with the degree of histological activity [67,70,71]. Consistent
with these results, the risk of overestimating liver stiffness values
has been reported in case of ALT ﬂares in patients with acute viral
hepatitis or chronic hepatitis B [72–74] as well as in cases of
extrahepatic cholestasis [75] or congestive heart failure [76]. Also
TE measurements need to be standardized, since in patients with
cirrhosis its values increased by over 25% after a light meal, as
compared with fasting patients [77].Conclusions and perspectives
TE is currently insufﬁcient to conﬁdently predict the presence of
oesophageal varices in clinical practice but rather, given its likely
prognostic value in cirrhosis, to offer a mean for rapid discrimina-
tion of different steps of progression within the stage of compen-
sated cirrhosis. This will greatly help allocating cirrhotic patients
in different categories of risk and guide the need for further eval-
uation with HVPG measurement and upper GI endoscopy.
TE is not expected to replace HVPG measurement in assessing
the response to the treatment of portal hypertension and the prog-
nosis of acute variceal bleeding. This will remain the domain of
invasive procedures and future developments should be aimed
at making easier to obtain repeated measurements along the fol-
low-up. There is insufﬁcient data as to whether TE may substitute
HVPG in indications such as prognosis of liver resection for HCC,
although it is likely that patients with high TE values (i.e.
>14 kPa)may be reasonably excluded as candidates for liver resec-
tion and may not need and HVPG measurement to conﬁdently
identify severe recurrence of HCV after liver transplantation.
Also studies comparing TE with other non invasive methods
for the detection of OV are awaited. However, when designing
future studies, the weaknesses of the existing gold standard
should probably be taken into account. In particular, attention
should be paid to improving the interpretation of endoscopy
and reducing the variability of results.
Finally, other techniques such as the measurement of spleen
stiffness [78] may also become available and deserved to be fur-
ther evaluated in comparison or in combination with TE.Conﬂict of interest
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manuscript.
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